Denmark’s Veloxis said Monday that it has now launched its drug Envarsus XR on the US market. It is an oral medicine for the prophylaxis of rejection in kidney transplant patients. Veloxis says it will be marketing the drug through its own dedicated sales force in the US.
"Our sales force is now out in the field detailing transplant physicians about the potential benefits of Envarsus XR and our patient support services, for which we strive to be best-in-class, are now active. We expect prescription growth to be gradual and steady as existing transplant recipients are converted to Envarsus XR and we look forward to communicating the progress of our launch in the coming quarters," says CEO Bill Polvino according to a press release.